MedTrace Logo

Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico

NCT04793243 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2021-03-11

No results posted yet for this study

Summary

The immunomodulatory effects of vitamin D are known to be beneficial in viral infections, it is also known that its deficiency is associated with a worse prognosis of COVID-19. This study aimed to determine the baseline vitamin D serum concentrations in asymptomatic or mildly symptomatic COVID-19 outpatients, as well as to evaluate the effects of supplementation with 10,00 IU/daily of vitamin D3 and its relationship with biochemical parameters and clinical features.

Conditions

  • Covid19

Interventions

DIETARY_SUPPLEMENT

Vitamin D3

Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • José F Muñoz-Valle, Dr. · University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-17
Primary Completion
2020-10-10
Completion
2020-10-24

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04793243 on ClinicalTrials.gov